Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer

Lung Cancer

Volumn 70, Issue 2, 2010, Pages 188-194

  Um, Soo Jung ^a   Choi, Young Jin ^b   Shin, Ho Jin ^b   Son, Cheol Hun ^c   Park, You Soo ^c   Roh, Mee Sook ^a   Kim, Yun Seong ^b   Kim, Young Dae ^b   Lee, Soo Keol ^a   Jung, Min Ho ^a   Lee, Min Ki ^b   Son, Choonhee ^a   Choi, Pil Jo ^a   Chung, Jooseop ^b   Kang, Chi Dug ^b   Lee, Eun Yup ^b  

^a Dong A University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Binex Co Ltd   (South Korea)

Author keywords

Dendritic cells; Electroporation; Immunotherapy; Non small cell lung carcinoma; Tumor vaccines

Indexed keywords

CISPLATIN; DENDRITIC CELL VACCINE; DOCETAXEL; GAMMA INTERFERON; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; ELECTROPORATION; FEMALE; HUMAN; IMMUNE RESPONSE; INTERFERON PRODUCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-GAMMA; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; TRANSPLANTATION, AUTOLOGOUS;

EID: 77957016923     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.02.006     Document Type: Article

References (22)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statics, 2002. CA: Cancer J Clin 2005, 55:74-108.
2. http://ups.kosis.kr/upload/magazine/new/yd/vd0006.xls.
3. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
4. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immuno editing: from immunosurveillance to tumor espcape. Nat Immunol 2002, 3:991-998.
5. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
6. Gilboa E., Nair S.K., Lyerly H.K. Immunotherapy of cancer with dendritic cell based vaccines. Cancer Immunol Immunother 1998, 46:82-87.
7. Cranmer L.D., Trevor K.T., Hersh E.M. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004, 53:275-306.
8. Tarte K., Klein B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 1999, 13:653-663.
9. Kim K.W., Kim S.H., Jang J.H., Lee E.Y., Park S.W., Um J.H., et al. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother 2004, 53:315-322.
10. National Cancer Institute. National Cancer Institute common toxicity criteria. [on-line]. http://ctep.info.nih.gov/reporting/index.html.
11. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 2000, 92:205-216.
12. Mukherji B., Chakraborty N.G., Yamasaki S., Okina T., Yamase H., Sporn J.R., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995, 9:8078-8082.
13. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest 2003, 21:873-886.
14. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L., et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138.
15. Nemunaitis J., Sterman D., Jablons D., Smith J.W., Fox B., Maples P., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:326-331.
16. Conrad C., Nestle F.O. Dendritic cell-based cancer therapy. Curr Opin Mol Ther 2003, 5:405-412.
17. Reid D.C. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001, 112:874-887.
18. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D. Lyerly HK migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999, 59:56-58.
19. Fong L., Brockstedt D., Benike C., Wu L., Engleman E.G. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001, 166:4254-4259.
20. Hirschowitz E.A., Foody T., Kryscio R., Dickson L., Sturgill J., Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004, 22:2808-2815.
21. Avigan D.E., Vasir B., George D.J., Oh W.K., Atkins M.B., McDermott D.F., et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007, 30:749-761.
22. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P., et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002, 8:1021-1032.